石药集团(01093.HK)：普卢格列汀达格列净二甲双胍缓释片在中国获临床试验批准

Core Viewpoint - The approval of the combination drug by the National Medical Products Administration of China marks a significant advancement in diabetes treatment, providing a new therapeutic option for patients with type 2 diabetes [1][2]. Group 1: Product Approval and Composition - The product, a combination of Ploglitazone, Dapagliflozin, and Metformin, is the first of its kind globally to receive clinical trial approval [1]. - Ploglitazone is a DPP-4 inhibitor that enhances insulin secretion and improves glucose sensitivity [1]. - Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion by reducing glucose reabsorption [1]. - Metformin is a biguanide that improves glucose tolerance and lowers both fasting and postprandial blood glucose levels [1]. Group 2: Clinical Application and Benefits - The approved clinical indication is for use in adults with type 2 diabetes who have inadequate blood sugar control with Metformin alone, in conjunction with diet and exercise [2]. - The complementary mechanisms of the three-drug combination effectively address multiple pathophysiological aspects of diabetes, enhancing blood sugar control [2]. - The product is expected to simplify treatment regimens, reduce the number of medications needed, and improve patient adherence to therapy, indicating high clinical development value [2].